Can a rheumatoid arthritis drug tame immunotherapy side effects?

NCT ID NCT04305145

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researchers will compare how many achieve symptom relief without needing long-term steroids after 7 weeks. The goal is to find a safer, more effective way to manage this common side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab (a drug that blocks inflammation)
What this could lead to: If it works, this could offer a more effective, steroid-free way to manage severe colitis caused by immunotherapy, allowing patients to better tolerate cancer treatment.
What could go wrong: This is a small, early-phase trial with only 42 participants. Infliximab may not work better than steroids, and it carries risks like infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG TOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemical colitis colitis Drug-Related Side Effects and Adverse Reactions melanoma metastatic melanoma skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG TOXICITY DRUG-INDUCED COLITIS IMMUNE-RELATED ADVERSE EVENT MELANOMA STAGE III MELANOMA STAGE IV SKIN CANCER STAGE III SKIN CANCER STAGE IV

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.